Top Companies in Lateral Flow Assays

The lateral flow assays market is expected to grow from USD 8.51 billion in 2025 to USD 12.52 billion by 2030 with a CAGR of 8.0%. The high prevalence of infectious diseases worldwide and the subsequent need for testing, rapid growth in the geriatric population, the rising use of home-based lateral flow assay devices, and the growing demand for POC testing are the major factors driving the growth of this market. However, inconsistent accuracy compared to other methods and the reluctance of doctors and patients to shift from traditional diagnostics restrain the growth of the lateral flow assays market.

Notable companies in this market include Abbott Laboratories (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), QuidelOrtho Corporation (US), Siemens AG (Germany), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US), Revvity, Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), Merck KGaA (Germany), Surmodics, Inc. (US), and OraSure Technologies Inc. (US) among others. The leading companies in the market focus on higher sales, product launches, and product approvals.

To know about the assumptions considered for the study download the pdf brochure

Abbott Laboratories (US)

Abbott is the leading player in the global lateral flow assay market, accounting for the largest share of the global LFA market in 2024. Its dominance stems from a diverse LFA portfolio encompassing infectious disease, cardiac, and consumer-based diagnostics, backed by robust continuous innovation. Abbott’s strategic investments in reader-enabled and multiplex LFA formats, along with a strong global manufacturing footprint and R&D pipeline, reinforce its leadership position. The company’s focus on benchtop reader integration and pharma/biotech QC applications signals its intent to stay ahead in high-value LFA segments, ensuring sustained competitive advantage.

F. Hoffman-La Roche Ltd. (Switzerland)

Roche is a key leader in the lateral flow assay space, accounting for the second-largest share of the global market. Known for its high-sensitivity LFA products, Roche has made strides in digital-read capabilities and advanced sandwich assays targeting infectious diseases and oncology screening. Its regular product refreshes and R&D expansion, including enhanced multiplex LFA formats, reflect its ongoing commitment to innovation. Roche’s established global footprint and investment in smart diagnostic technologies position it as a formidable force in premium LFA segments, strengthening its presence during market transitions.

Danaher Corporation (US)

Danaher commands a significant share of the LFA market. Beyond components, its Life Sciences portfolio, bolstered by acquisitions like Pall and Cytiva, equips Danaher to influence next-generation LFA platforms for process development and QC in biopharma. In 2023, Danaher further solidified its position by acquiring Abcam, enhancing capabilities in research-stage diagnostics. With a strong operational backbone, strategic M&A strategy, and growing role in supplying membranes, conjugates, and benchtop instruments, Danaher is a key enabler of LFA innovation, powering the ecosystem behind major LFA brands.

Market Ranking

The lateral flow assay (LFA) market is primarily led by Abbott Laboratories (US), F.�Hoffmann La Roche Ltd. (Switzerland), and Danaher Corporation (US). These companies together command the largest share of the global LFA market due to their comprehensive portfolios, ongoing innovation, robust global footprint, and strategic expansion efforts. Abbott Laboratories holds a dominant position in global LFA revenue. Its portfolio spans infectious disease, cardiac, consumer, and veterinary diagnostics, highlighted by innovations like reader-integrated and multiplex assay formats. Abbott’s global manufacturing footprint, continuous R&D investment, and strategic expansions ensure its leading advantage in high-value LFA applications. F. Hoffmann La Roche Ltd. secures the second-largest market share with a reputation for high-sensitivity assays. Its investments in digital-read technologies and advanced sandwich/multiplex LFAs targeting infectious diseases and oncology reflect a sustained emphasis on innovation. A robust global presence and regulatory credentials empower Roche’s position in premium diagnostic segments. Danaher Corporation plays a pivotal role both as a direct LFA provider and a key component enabler, leveraging its Life Sciences segment, including Pall, Cytiva, and Abcam, to support assay development and QC. Danaher’s strategic acquisitions and supply capabilities in membranes, conjugates, and reader instruments have established it as the backbone of the LFA ecosystem, catering to biopharma and clinical diagnostics.

Related Reports:

Lateral Flow Assay Market by Product (Kits, Readers), Application (STI, HEP, TB, Cardiac Marker, Pregnancy, Drug Abuse, Food Safety), Sample (Blood, Urine, Saliva), Technique (Sandwich, Competitive), End User (Hospitals), and Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103,
Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com